TabletsClinical Overview
Donepezil and Memantine is a complementary dual-mechanism formulation for moderate-to-severe dementia. Donepezil, a reversible piperidine acetylcholinesterase inhibitor, increases acetylcholine concentrations at cerebral synapses, while memantine, an uncompetitive NMDA receptor antagonist, protects cholinergic neurons against pathological chronic glutamate-mediated excitotoxicity. Indicated for moderate-to-severe dementia of the Alzheimer's type.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally once daily in the evening immediately before bedtime with water, with or without food. Swallow whole; do not crush or chew. Maintain regular daily administration.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Diarrhea, nausea, insomnia, fatigue, muscle cramps, dizziness, headache, anorexia. Rare/Severe: Bradycardia, syncope, QT prolongation, peptic ulceration/GI bleeding, and seizures.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Cholinesterase inhibitors cause vagotonic effects; exercise caution in patients with sick sinus syndrome, bradycardia, or cardiac conduction abnormalities. Caution in patients with peptic ulcer disease or severe asthma/COPD.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered medical practitioner or qualified pharmacist before initiating, modifying, or substituting any medication regimen.
Donepezil Hydrochloride Tablets 10mg
Donepezil Hydrochloride is a reversible, non-competitive, highly selective piperidine acetylcholinesterase (AChE) inhibitor on the WHO Model List of Essential Medicines. It increases synaptic acetylcholine availability in the cerebral cortex and hippocampus by inhibiting its breakdown. Indicated for mild, moderate, and severe dementia of the Alzheimer's type.
Memantine Hydrochloride Tablets 10mg
Memantine Hydrochloride is an uncompetitive, low-to-moderate affinity, voltage-dependent N-methyl-D-aspartate (NMDA) receptor antagonist. Pathological chronic exposure to high glutamate concentrations produces excitotoxic neuronal death in Alzheimer's disease; memantine blocks pathological tonic glutamate influx through NMDA channels while preserving physiological phasic neurotransmission necessary for learning and memory. Indicated for moderate-to-severe dementia of the Alzheimer's type.
Donepezil Tablets 5 mg
Donepezil Hydrochloride is a reversible, non-competitive, highly selective piperidine acetylcholinesterase (AChE) inhibitor on the WHO Model List of Essential Medicines. It increases synaptic acetylcholine availability in the cerebral cortex and hippocampus by inhibiting its breakdown. Indicated for mild, moderate, and severe dementia of the Alzheimer's type.
Donepezil 5mg + Memantine 10mg Tablets
Donepezil and Memantine is a complementary dual-mechanism formulation for moderate-to-severe dementia. Donepezil, a reversible piperidine acetylcholinesterase inhibitor, increases acetylcholine concentrations at cerebral synapses, while memantine, an uncompetitive NMDA receptor antagonist, protects cholinergic neurons against pathological chronic glutamate-mediated excitotoxicity. Indicated for moderate-to-severe dementia of the Alzheimer's type.